STOCK TITAN

Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) has received a Notice of Allowance from the USPTO for a composition-of-matter patent covering tablet forms of benzgalantamine (ZUNVEYL), their treatment for mild to moderate Alzheimer's disease. This patent, once issued, will provide protection for ZUNVEYL's current formulation in the United States through 2044.

The Notice of Allowance signifies that the USPTO has determined the claimed invention is patentable and a patent should be granted. This milestone strengthens Alpha Cognition's ability to extend patent life beyond 2042 to 2044 in the U.S. market. The company plans to pursue similar patent approvals globally.

CEO Michael McFadden stated that this allowance provides an important layer of proprietary intellectual property protection for ZUNVEYL, their FDA-approved medication for mild to moderate Alzheimer's disease.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ha ricevuto una Notifica di Concessione dal USPTO per un brevetto sulla composizione della materia che copre le forme in compresse di benzgalantamina (ZUNVEYL), il loro trattamento per l'Alzheimer da lieve a moderato. Questo brevetto, una volta emesso, garantirà protezione per la formulazione attuale di ZUNVEYL negli Stati Uniti fino al 2044.

La Notifica di Concessione indica che l'USPTO ha stabilito che l'invenzione rivendicata è brevettabile e che un brevetto dovrebbe essere concesso. Questo traguardo rafforza la capacità di Alpha Cognition di estendere la durata del brevetto oltre il 2042 fino al 2044 nel mercato statunitense. L'azienda prevede di perseguire approvazioni di brevetti simili a livello globale.

Il CEO Michael McFadden ha dichiarato che questa concessione fornisce uno strato importante di protezione della proprietà intellettuale esclusiva per ZUNVEYL, il loro farmaco approvato dalla FDA per l'Alzheimer da lieve a moderato.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ha recibido un Aviso de Concesión de la USPTO para un patente de composición de materia que cubre las formas de tabletas de benzgalantamina (ZUNVEYL), su tratamiento para el Alzheimer leve a moderado. Esta patente, una vez emitida, proporcionará protección para la formulación actual de ZUNVEYL en los Estados Unidos hasta 2044.

El Aviso de Concesión significa que la USPTO ha determinado que la invención reclamada es patentable y se debe conceder un patente. Este hito fortalece la capacidad de Alpha Cognition para extender la vida del patente más allá de 2042 hasta 2044 en el mercado estadounidense. La compañía planea buscar aprobaciones de patente similares a nivel global.

El CEO Michael McFadden declaró que esta concesión proporciona una capa importante de protección de propiedad intelectual exclusiva para ZUNVEYL, su medicamento aprobado por la FDA para el Alzheimer leve a moderado.

알파 코그니션 주식회사 (CSE: ACOG) (OTCQB: ACOGF)는 USPTO로부터 물질 조성 특허 안내를 받아, 알츠하이머 질환의 경증에서 중등증 치료제인 벤즈갈란타민(ZUNVEYL)의 정제 형태에 대한 허가를 받았습니다. 이 특허는 발급되면 ZUNVEYL의 현재 제형에 대해 미국에서 2044년까지 보호를 제공합니다.

안내 공지는 USPTO가 청구된 발명이 특허가 가능하다고 판단했음을 나타내며, 특허가 부여되어야 함을 의미합니다. 이 이정표는 알파 코그니션이 미국 시장에서 2042년에서 2044년으로 특허 기간을 연장할 수 있는 능력을 강화합니다. 이 회사는 글로벌 차원에서 유사한 특허 승인도 추진할 계획입니다.

CEO 마이클 맥패든은 이 허가가 ZUNVEYL에 대한 중요한 독점 지식 재산 보호 층을 제공한다고 언급했습니다. 이는 그들의 FDA 승인 약물로서의 경증 및 중등도 알츠하이머 질환 치료제입니다.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) a reçu un Avis de Concession de l'USPTO pour un brevet sur la composition de matière couvrant les formes de comprimés de benzgalantamine (ZUNVEYL), leur traitement pour la maladie d'Alzheimer légère à modérée. Ce brevet, une fois délivré, offrira une protection pour la formulation actuelle de ZUNVEYL aux États-Unis jusqu'en 2044.

L'Avis de Concession indique que l'USPTO a déterminé que l'invention revendiquée est brevetable et qu'un brevet doit être accordé. Ce jalon renforce la capacité d'Alpha Cognition à étendre la durée du brevet au-delà de 2042 jusqu'en 2044 sur le marché américain. L'entreprise prévoit de poursuivre des approbations de brevet similaires à l'échelle mondiale.

Le PDG Michael McFadden a déclaré que cette concession fournit une couche importante de protection de la propriété intellectuelle exclusive pour ZUNVEYL, leur médicament approuvé par la FDA pour la maladie d'Alzheimer légère à modérée.

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) hat vom USPTO eine Mitteilung über die Genehmigung für ein Materiekompositionspatent erhalten, das die Tablettenformen von Benzgalantamin (ZUNVEYL), ihrer Behandlung für leicht bis mittelschwere Alzheimer-Erkrankungen, abdeckt. Dieses Patent, sobald es erteilt wird, bietet Schutz für die aktuelle Formulierung von ZUNVEYL in den Vereinigten Staaten bis 2044.

Die Mitteilung über die Genehmigung bedeutet, dass das USPTO festgestellt hat, dass die beanspruchte Erfindung patentierbar ist und ein Patent erteilt werden sollte. Dieser Meilenstein stärkt die Fähigkeit von Alpha Cognition, die Patentenutzerrechte über das Jahr 2042 hinaus bis 2044 im US-Markt auszudehnen. Das Unternehmen plant, ähnliche Patentgenehmigungen weltweit anzustreben.

CEO Michael McFadden erklärte, dass diese Genehmigung eine wichtige Schicht des exklusiven geistigen Eigentumsschutzes für ZUNVEYL, ihr von der FDA zugelassenes Medikament für leicht bis mittelschwere Alzheimer-Erkrankungen, bietet.

Positive
  • Received Notice of Allowance for composition-of-matter patent for ZUNVEYL
  • Patent protection extended through 2044 in the United States
  • Strengthens proprietary intellectual property protection for lead asset
Negative
  • None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 18/434,155, entitled “Coated Tablets for pH-Dependent Release of benzgalantamine,” which includes claims covering tablet forms of benzgalantamine (ZUNVEYL). This composition of matter patent, once issued, provides protection for the current formulation of ZUNVEYL and complements other patents that the company holds for benzgalantamine and provides protection in the United States through 2044. A Notice of Allowance is issued after the USPTO makes the determination that the claimed invention is patentable, and a patent should be granted from an application.

This Notice of Allowance is a critical milestone in our mission to develop transformative therapies for Alzheimer’s disease. It not only recognizes the innovative nature of our research but also strengthens the Company’s ability to extend patent life beyond 2042 to 2044 in the United States market. The Company plans to pursue patent approvals throughout territories in the rest of the world for this invention.

"Allowance of this composition-of-matter patent application, covering a tablet form of benzgalantamine, provides another important layer of proprietary intellectual property protection for our lead asset, ZUNVEYL, an FDA-approved medication for the treatment of mild to moderate Alzheimer’s disease," said Michael McFadden, Chief Executive Officer of Alpha Cognition.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI, which latter candidate is expected to be out-licensed to Alpha Seven Therapeutics Inc. (“Alpha Seven”) a newly incorporated related entity.

This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s and Alpha Seven’s ability to obtain funding in an amount and on terms satisfactory to the Company to continue to implement its business plan, the Company’s potential uses of any funding it does receive, the Company’s ability to adequately implement its business plan upon receipt of funding, the Company’s and Alpha Seven’s ability to continue to pursue financings in the future, the Company’s future plans to uplist to Nasdaq, the Company’s continued conversations with strategic partners, the Company’s and Alpha Seven’s ability to obtain alternative and non-dilutive funding, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s and Alpha Seven’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding the ability of us and Alpha Seven to raise sufficient capital, including funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1 registration statement as filed with the SEC on June 14, 2024 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

For further information:

Michael McFadden, CEO

Tel: 1-858-344-4375

info@alphacognition.com

Source: Alpha Cognition Inc.

FAQ

What patent did Alpha Cognition (ACOGF) receive a Notice of Allowance for?

Alpha Cognition received a Notice of Allowance from the USPTO for a composition-of-matter patent covering tablet forms of benzgalantamine (ZUNVEYL), their treatment for mild to moderate Alzheimer's disease.

How long will the new patent protect ZUNVEYL (ACOGF) in the United States?

The new patent, once issued, will provide protection for ZUNVEYL's current formulation in the United States through 2044.

What is ZUNVEYL by Alpha Cognition (ACOGF) used to treat?

ZUNVEYL is an FDA-approved medication for the treatment of mild to moderate Alzheimer's disease.

Does Alpha Cognition (ACOGF) plan to pursue patent approvals in other countries?

Yes, Alpha Cognition plans to pursue similar patent approvals for ZUNVEYL throughout territories in the rest of the world.

ALPHA COGNITION INC NEW

OTC:ACOGF

ACOGF Rankings

ACOGF Latest News

ACOGF Stock Data

35.50M
149.58M
Biotechnology
Healthcare
Link
United States of America
Vancouver